| Literature DB >> 26047609 |
Shilpi Aggarwal1, Atish Gheware2,3, Anurag Agrawal4,5, Saurabh Ghosh6, Bhavana Prasher7,8, Mitali Mukerji9,10,11.
Abstract
BACKGROUND: Extreme constitution "Prakriti" types of Ayurveda exhibit systemic physiological attributes. Our earlier genetic study has revealed differences in EGLN1, key modulator of hypoxia axis between Prakriti types. This was associated with differences in high altitude adaptation and susceptibility to high altitude pulmonary edema (HAPE). In this study we investigate other molecular differences that contribute to systemic attributes of Prakriti that would be relevant in predictive marker discovery.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26047609 PMCID: PMC4457985 DOI: 10.1186/s12967-015-0542-9
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
SNPs that show significant differences between the Prakriti groups after FDR correction for multiple testing set at a threshold of significance of p < 0.05
| Gene | SNP | Variation | Comparison | Allele | Allele frequency 1 | Allele frequency 2 | P value |
|---|---|---|---|---|---|---|---|
| Allele frequency (1 vs. 2) | |||||||
| EPR | rs1171271 | C/T | PvsK | C | 0.46 | 0.13 | 5.40E−05 |
| OR6K3 | rs857703 | A/G | KvsV | A | 0.11 | 0.43 | 4.44E−05 |
| UCP2 | rs660339 | A/G | KvsV | A | 0.15 | 0.49 | 4.23E−05 |
| OLR1 | rs3741860 | A/G | VvsP | G | 0.49 | 0.14 | 2.87E−05 |
| OLR1 | rs3741860 | A/G | PvsK | G | 0.14 | 0.53 | 6.35E−06 |
| SPTA1 | rs857691 | C/T | PvsK | T | 0.40 | 0.06 | 1.63E−05 |
| SPTA1 | rs857721 | A/T | PvsK | A | 0.43 | 0.05 | 6.05E−07 |
|
| rs1063856 | C/T | PvsK | C | 0.05 | 0.37 | 1.55E−05 |
| OR10Z1 | rs857685 | A/C | PvsK | C | 0.41 | 0.05 | 1.46E−06 |
Figure 1Representation of allele frequencies of common variations amongst extreme constitution types. A representative set of SNPs that show significant difference between the constitution types Kapha (K), Pitta (P), Vata (V) and differ from the VPK/IE pool are depicted. The gene and SNP with the alleles are given in each panel. IE represents individuals with heterogeneous phenotypes from Indo-European populations and VPK represents individuals of different constitution types pooled into a single group.
Figure 2Distribution of ancestral ‘C’ allele (rs1063856) frequency of VWF gene associated with thrombosis in diverse IGVC and HGDP-CEPH populations. a Frequency in the 24 IGV populations. TB-N-IP1, a population from high altitude has fixation for the derived allele. b Spatial frequency map of rs1063856 in the HGDP-CEPH panel of 55 populations retrieved from HGDP selection browser. There is a clinal variation in the frequency of derived allele as populations moved out of Africa.
Figure 3Distribution of frequency of homozygous genotype scores (4) for protective alleles at both loci EGLN1. rs480902 and VWF rs1063856 in diverse HGDP-CEPH populations from different altitudes. Diverse populations especially from East Asia residing at high altitude selectively retain the combination of ancestral allele of EGLN1 and derived allele of VWF.
Figure 4Effect of chemical inhibition of PHD or EGLN in mouse on various blood parameters. a Schematic representation of DHB experiment protocol. PHD inhibition was done by giving DHB (ethyl-3, 4, dihydroxybenzoic acid) treatment in mice. DHB was administered from day 1 to 7. On day 8 mice tail bleeding assay was performed. b Decrease in tail bleeding time of mice treated with DHB in a dose dependent manner. c, d PHD inhibition in mice by chemical DHB treatment leads to increase in total platelet count and its distribution width (considered here as active platelet parameter). Both parameters were assessed through automatic hematology analyzer in mouse whole blood (anticoagulated) as described in methods. e, f ELISA for estimation of HIF-1α and VWF antigen levels in mouse plasma after PHD inhibition. ND not detectable. Data shown as mean ± SEM. *p ≤ 0.05, ***p ≤ 0.001 (n = 6 per group).
Figure 5Knockdown of PHD2 by siRNA in mice leads to pro-thrombotic phenotype. a Schematic representation of siRNA experiment protocol. Scrambled or PHD2 siRNA was given intra-nasally to mice on day 1, 3 and 5. On day 6 mice were subjected to tail bleeding assay. b Tail bleeding time (in seconds) measured in mice treated with siRNA (Scrambled or PHD2) or in untreated (naïve) mice groups as described in methods. c, d Total and active platelet count assessed in mouse whole blood via flow cytometry. CD62P and CD-41 antibody were used to label total and active platelets respectively e, f ELISA for estimation of VWF and HIF-1α antigen levels in mouse plasma. Data shown as mean ± SEM. *p ≤ 0.05, ***p ≤ 0.001 (n = 5–6 per group).